Beximco Pharmaceuticals raked in Tk 144.54 crore profit in the July-September quarter of the current financial year of 2022-23. 

The profit is down 1.22 per cent from Tk 146.32 crore it made during the same quarter a year earlier. 

Thus, the consolidated earnings per share (EPS) were Tk 3.24 in July-September against Tk 3.28 during the same quarter in 2021, according to the unaudited financial statements of the pharmaceutical company.

The consolidated EPS declined because of the decreased EPS of the subsidiary Nuvista Pharma and the loss incurred by the other newly acquired subsidiary, Synovia Pharma, said Beximco Pharmaceuticals in a filing on the Dhaka Stock Exchange.

The consolidated net operating cash flow per share fell to Tk 1.53 in the quarter versus Tk 4.46 reported during the same July-September of 2021, due to an increased working capital investment consequent to the record devaluation of the taka and the increased price of materials and higher domestic inflation, it said.

The net asset value per share was Tk 94.25 on September 30 this year and Tk 86.31 on the same day last year.

Beximco pharma shares were down 3.04 per cent on the DSE yesterday.